by admin | Oct 8, 2019 | Clinical Trials
The narcolepsy drug, developed by Irish company Jazz Pharmaceuticals, has a lower salt content than the current treatment Xyrem, making it more suitable for patients at risk of cardiovascular disease. In a 200-patient phase III trial that finished in July, Jazz...
by admin | Sep 4, 2019 | Funding
Rouen-based medtech startup Robocath designs, develops, and commercializes cardiovascular robotic systems for the treatment of vascular diseases such as heart attack and stroke. The startup has raised €5 million to support the rollout of its robotic platform in...
